Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen

被引：12

作者：

Liew, Elena ^{[1
]}

Atenafu, Eshetu G. ^{[2
]}

Schimmer, Aaron D. ^{[1
]}

Yee, Karen W. L. ^{[1
]}

Schuh, Andre C. ^{[1
]}

Minden, Mark D. ^{[1
]}

Gupta, Vikas ^{[1
]}

Brandwein, Joseph M. ^{[1
]}

机构：

[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada

[2] Univ Toronto, Princess Margaret Hosp, Dept Biostat, Toronto, ON M5G 2M9, Canada

来源：

LEUKEMIA RESEARCH | 2012年 / 36卷 / 12期

关键词：

Leukemia; Lymphoblastic; Acute; Chemotherapy; Allogeneic stem cell transplantation; MINIMAL RESIDUAL DISEASE; STANDARD-RISK; THERAPY; MRD; AGE;

D O I：

10.1016/j.leukres.2012.08.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We analyzed the outcome of 46 patients with acute lymphoblastic leukemia (ALL) who relapsed following treatment with a pediatric-based protocol; 34 received intensive re-induction chemotherapy, with a CR2 rate of 62%, median overall survival (OS) 7.8 months, median relapse-free survival 5.2 months and one year OS 19%. Allogeneic HSCT was performed in 8 patients in CR2/3, with a median OS 2.2 months. OS was superior in patients who relapsed after completion of chemotherapy, compared to those relapsing on treatment. The outcome of adult ALL relapsing after treatment was therefore poor, and novel salvage strategies are needed to improve outcomes. (C) 2012 Published by Elsevier Ltd.

引用

页码：1517 / 1520

页数：4

共 50 条

[41] Treatment of older patients with acute lymphoblastic leukemia
Goekbuget, Nicola
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 573 - 579
[42] Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
Graiqevci-Uka, Violeta
Behluli, Emir
Spahiu, Lidvana
Liehr, Thomas
Temaj, Gazmend
CURRENT PEDIATRIC REVIEWS, 2023, 19 (02) : 150 - 156
[43] Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
A W Rijneveld
B van der Holt
S M G J Daenen
B J Biemond
O de Weerdt
P Muus
J Maertens
V Mattijssen
H Demuynck
M C J C Legdeur
P W Wijermans
S Wittebol
F M Spoelstra
A W Dekker
G J Ossenkoppele
R Willemze
J J Cornelissen
Leukemia, 2011, 25 : 1697 - 1703
[44] Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with Pediatric-Inspired Protocols in Adolescent and Young Adults and Adult Patients with Acute Lymphoblastic Leukemia
Oanunu, Uriel
Even-Zohar, Noa Gross
Aumann, Shlomzion
Vainstein, Vladimir
Gural, Alexander
Gatt, Moshe E.
Haran, Arnon
Nachmias, Boaz
ACTA HAEMATOLOGICA, 2025,
[45] Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia
Li, Xiaoli
Liu, Limin
Zhang, Yanming
Qu, Qi
Yao, Yao
Wang, Tong
Jiao, Wenjing
Wu, Depei
LEUKEMIA RESEARCH, 2015, 39 (11) : 1201 - 1206
[46] The Effects of Pediatric Acute Lymphoblastic Leukemia Treatment on Cardiac Repolarization
Lazar, Diana R.
Cainap, Simona
Lazar, Florin Leontin
Maniu, Dana
Blag, Cristina
Bota, Madalina
Colceriu, Marius C.
Zdrenghea, Mihnea
CHILDREN-BASEL, 2024, 11 (10):
[47] Risk-adapted Treatment of Pediatric Acute Lymphoblastic Leukemia
Jeha, Sima
Pui, Ching-Hon
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (05) : 973 - +
[48] Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia Current and Emerging Treatments
Martin, Alissa
Morgan, Elaine
Hijiya, Nobuko
PEDIATRIC DRUGS, 2012, 14 (06) : 377 - 387
[49] How I treat relapsed acute lymphoblastic leukemia in the pediatric population
Hunger, Stephen P.
Raetz, Elizabeth A.
BLOOD, 2020, 136 (16) : 1803 - 1812
[50] Monoclonal antibodies in frontline therapy of adult acute lymphoblastic leukemia: A step ahead
Ribera, Josep-Maria
Torrent, Anna
MEDICINA CLINICA, 2022, 158 (10): : 476 - 477

← 1 2 3 4 5 →